

BACKGROUND NOTE: Each year WHO and UNICEF jointly review reports submitted by Member States regarding national immunization coverage, finalized survey reports as well as data from the published and grey literature. Based on these data, with due consideration to potential biases and the views of local experts, WHO and UNICEF attempt to distinguish between situations where the available empirical data accurately reflect immunization system performance and those where the data are likely to be compromised and present a misleading view of immunization coverage while jointly estimating the most likely coverage levels for each country.

WHO and UNICEF estimates are country-specific; that is to say, each country's data are reviewed individually, and data are not borrowed from other countries in the absence of data. Estimates are not based on ad hoc adjustments to reported data; in some instances empirical data are available from a single source, usually the nationally reported coverage data. In cases where no data are available for a given country/vaccine/year combination, data are considered from earlier and later years and interpolated to estimate coverage for the missing year(s). In cases where data sources are mixed and show large variation, an attempt is made to identify the most likely estimate with consideration of the possible biases in available data. For methods see:

*Burton et al. 2009. WHO and UNICEF estimates of national infant immunization coverage: methods and processes.

*Burton et al. 2012. A formal representation of the WHO and UNICEF estimates of national immunization coverage: a computational logic approach.

*Brown et al. 2013. An introduction to the grade of confidence used to characterize uncertainty around the WHO and UNICEF estimates of national immunization coverage.

DATA SOURCES.

ADMINISTRATIVE coverage: Reported by national authorities and based on aggregated administrative reports from health service providers on the number of vaccinations administered during a given period (numerator data) and reported target population data (denominator data). May be biased by inaccurate numerator and/or denominator data.

OFFICIAL coverage: Estimated coverage reported by national authorities that reflects their assessment of the most likely coverage based on any combination of administrative coverage, survey-based estimates or other data sources or adjustments. Approaches to determine OFFICIAL coverage may differ across countries.

SURVEY coverage: Based on estimated coverage from population-based household surveys among children aged 12-23 months or 24-35 months following a review of survey methods and results. Information is based on the combination of vaccination history from documented evidence or caregiver recall. Survey results are considered for the appropriate birth cohort based on the period of data collection.

ABBREVIATIONS

BCG: percentage of births who received one dose of Bacillus Calmette Guerin vaccine.

DTP1 / DTP3: percentage of surviving infants who received the 1st / 3rd dose, respectively, of diphtheria and tetanus toxoid with pertussis containing vaccine.

Pol3: percentage of surviving infants who received the 3rd dose of polio containing vaccine. May be either oral or inactivated polio vaccine.

IPV1: percentage of surviving infants who received at least one dose of inactivated polio vaccine. In countries utilizing an immunization schedule recommending either (i) a primary series of three doses of oral polio vaccine (OPV) plus at least one dose of IPV where OPV is included in routine

immunization and/or campaign or (ii) a sequential schedule of IPV followed by OPV, WHO and UNICEF estimates for IPV1 reflect coverage with at least one routine dose of IPV among infants <1 year of age among countries. For countries utilizing IPV containing vaccine use only, i.e., no recommended dose of OPV, the WHO and UNICEF estimate for IPV1 corresponds to coverage for the 1st dose of IPV.

Production of IPV coverage estimates, which begins in 2015, results in no change of the estimated coverage levels for the 3rd dose of polio (Pol3). For countries recommending routine immunization with a primary series of three doses of IPV alone, WHO and UNICEF estimated Pol3 coverage is equivalent to estimated coverage with three doses of IPV. For countries with a sequential schedule, estimated Pol3 coverage is based on that for the 3rd dose of polio vaccine regardless of vaccine type.

MCV1: percentage of surviving infants who received the 1st dose of measles containing vaccine. In countries where the national schedule recommends the 1st dose of MCV at 12 months or later based on the epidemiology of disease in the country, coverage estimates reflect the percentage of children who received the 1st dose of MCV as recommended.

MCV2: percentage of children who received the 2nd dose of measles containing vaccine according to the nationally recommended schedule.

RCV1: percentage of surviving infants who received the 1st dose of rubella containing vaccine. Coverage estimates are based on WHO and UNICEF estimates of coverage for the dose of measles containing vaccine that corresponds to the first measles-rubella combination vaccine. Nationally reported coverage of RCV is not taken into consideration nor are the data represented in the accompanying graph and data table.

HepBB: percentage of births which received a dose of hepatitis B vaccine within 24 hours of delivery. Estimates of hepatitis B birth dose coverage are produced only for countries with a universal birth dose policy. Estimates are not produced for countries that recommend a birth dose to infants born to HepB virus-infected mothers only or where there is insufficient information to determine whether vaccination is within 24 hours of birth.

HepB3: percentage of surviving infants who received the 3rd dose of hepatitis B containing vaccine following the birth dose.

Hib3: percentage of surviving infants who received the 3rd dose of Haemophilus influenzae type b containing vaccine.

RotaC: percentage of surviving infants who received the final recommended dose of rotavirus vaccine, which can be either the 2nd or the 3rd dose depending on the vaccine.


PcV3: percentage of surviving infants who received the 3rd dose of pneumococcal conjugate vaccine. In countries where the national schedule recommends two doses during infancy and a booster dose at 12 months or later based on the epidemiology of disease in the country, coverage estimates may reflect the percentage of surviving infants who received two doses of PcV prior to the 1st birthday.

YFV: percentage of surviving infants who received one dose of yellow fever vaccine in countries where YFV is part of the national immunization schedule for children or is recommended in at risk areas; coverage estimates are annualized for the entire cohort of surviving infants.

Disclaimer: All reasonable precautions have been taken by the World Health Organization and United Nations Children's Fund to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization or United Nations Children's Fund be liable for damages arising from its use.

Iraq - BCG

IRQ - BCG



Description:

- 2020: Estimate based on coverage reported by national government. GoC=R+ D+
- 2019: Estimate based on coverage reported by national government. GoC=R+ D+
- 2018: Estimate based on coverage reported by national government. Programme reports two month vaccine stock-out at national level. GoC=R+ S+ D+
- 2017: Estimate based on coverage reported by national government. Estimate of 92 percent changed from previous revision value of 96 percent. GoC=R+ S+ D+
- 2016: Estimate based on coverage reported by national government supported by survey. Survey evidence of 95 percent based on 1 survey(s). Programme reports an unexplained decline in the target population of 15 percent from that reported in 2015. Programme reports four month vaccine stock-out at national level. Estimate of 87 percent changed from previous revision value of 90 percent. Estimate challenged by: D-
- 2015: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 94 percent based on 1 survey(s). Estimate challenged by: R-
- 2014: Reported data calibrated to 2010 and 2015 levels. Estimate challenged by: R-S-
- 2013: Reported data calibrated to 2010 and 2015 levels. Estimate challenged by: D-R-
- 2012: Reported data calibrated to 2010 and 2015 levels. Reported data excluded because 106 percent greater than 100 percent. Reported data excluded due to an increase from 69 percent to 106 percent with decrease 93 percent. Estimate challenged by: D-R-
- 2011: Reported data calibrated to 2010 and 2015 levels. Reported data excluded due to decline in reported coverage from 86 percent to 69 percent with increase to 106 percent. Estimate challenged by: R-
- 2010: Estimate of 90 percent assigned by working group. Estimate is based on survey results. Estimate challenged by: D-R-
- 2009: Estimate of 92 percent assigned by working group. Estimate is based on survey results. Reported data excluded because 106 percent greater than 100 percent. Reported data excluded due to an increase from 83 percent to 106 percent with decrease 86 percent. Estimate challenged by: D-R-

| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | 92 | 90 | 94 | 99 | 99 | 99 | 94 | 87 | 92 | 95 | 98 | 99 |
| Estimate GoC | • | • | • | • | • | • | • | • | ••• | ••• | •• | •• |
| Official | 106 | 86 | 69 | 106 | 93 | 93 | 79 | 87 | 92 | 95 | 98 | 99 |
| Administrative | 106 | 86 | 69 | 106 | 93 | 93 | 79 | 87 | 92 | 95 | 98 | 99 |
| Survey | 92 | 90 | NA | NA | NA | NA | 94 | 95 | NA | NA | NA | NA |


The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Iraq - DTP1

IRQ - DTP1



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | 88 | 86 | 92 | 90 | 85 | 84 | 80 | 71 | 89 | 95 | 93 | 90 |
| Estimate GoC | • | • | • | • | • | • | ••• | • | ••• | •• | •• | •• |
| Official | 100 | 93 | 97 | 94 | 88 | 86 | 80 | 69 | 89 | 95 | 93 | 90 |
| Administrative | 100 | 93 | 97 | 94 | 88 | 86 | 77 | 69 | 89 | 95 | 93 | 90 |
| Survey | 88 | 86 | NA | NA | NA | NA | 84 | 86 | NA | NA | NA | NA |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2020: Estimate based on coverage reported by national government. GoC=R+ D+
- 2019: Estimate based on coverage reported by national government. GoC=R+ D+
- 2018: Estimate based on coverage reported by national government. Estimate of 95 percent changed from previous revision value of 92 percent. GoC=R+ D+
- 2017: Estimate based on coverage reported by national government. Estimate of 89 percent changed from previous revision value of 93 percent. GoC=R+ S+ D+
- 2016: Reported DTP1 lower than DTP3. Estimate based on estimated DTP3 and assumes no dropout. Programme reports five month vaccine stock-out at national level. Iraq Multiple Indicator Cluster Survey 2018 results ignored by working group. Survey may no reflect 2016 vaccine stockout. Reported data excluded due to decline in reported coverage from 80 percent to 69 percent with increase to 89 percent. Programme reports an unexplained decline in the target population of 15 percent from that reported in 2015. Estimate of 71 percent changed from previous revision value of 87 percent. Estimate challenged by: R-S-
- 2015: Estimate based on coverage reported by national government supported by survey. Survey evidence of 84 percent based on 1 survey(s). Programme reports a 5 month national level stock-out of DTP-HepB-Hib vaccine. GoC=R+ S+ D+
- 2014: Reported data calibrated to 2010 and 2015 levels. Programme reports four months stock-out at national level. Reported number of children vaccinated is increasing since 2012 but continues to fall short of the reported number of children vaccinated with DTP containing vaccines during 2011. Estimate of 84 percent changed from previous revision value of 82 percent. Estimate challenged by: D-R-
- 2013: Reported data calibrated to 2010 and 2015 levels. Estimate of 85 percent changed from previous revision value of 86 percent. Estimate challenged by: D-R-
- 2012: Reported data calibrated to 2010 and 2015 levels. DTP-HepB-Hib pentavalent and DTP-Hib tetravalent vaccines introduced in 2012. Estimate challenged by: D-R-
- 2011: Reported data calibrated to 2010 and 2015 levels. Estimate challenged by: D-R-
- 2010: Estimate of 86 percent assigned by working group. Estimate is based on survey results. Estimate challenged by: D-R-
- 2009: Estimate of 88 percent assigned by working group. Estimate is based on survey results. Estimate challenged by: D-R-

Iraq - DTP3

IRQ - DTP3



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | 78 | 74 | 81 | 72 | 73 | 73 | 68 | 71 | 81 | 86 | 84 | 74 |
| Estimate GoC | • | • | • | • | • | • | • | ••• | ••• | • | •• | •• |
| Official | 86 | 84 | 89 | 78 | 77 | 75 | 68 | 71 | 81 | 86 | 84 | 74 |
| Administrative | 86 | 84 | 89 | 78 | 77 | 75 | 68 | 71 | 81 | 86 | 84 | 74 |
| Survey | 73 | 70 | NA | NA | NA | NA | 64 | 69 | NA | NA | NA | NA |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2020: Estimate based on coverage reported by national government. GoC=R+ D+
- 2019: Estimate based on coverage reported by national government. GoC=R+ D+
- 2018: Estimate based on coverage reported by national government. Estimate of 86 percent changed from previous revision value of 84 percent. Estimate challenged by: S-
- 2017: Estimate based on coverage reported by national government. Estimate of 81 percent changed from previous revision value of 85 percent. GoC=R+ S+ D+
- 2016: Estimate based on coverage reported by national government supported by survey. Survey evidence of 73 percent based on 1 survey(s). Iraq Multiple Indicator Cluster Survey 2018 card or history results of 69 percent modified for recall bias to 73 percent based on 1st dose card or history coverage of 86 percent, 1st dose card only coverage of 73 percent and 3rd dose card only coverage of 62 percent. Programme reports an unexplained decline in the target population of 15 percent from that reported in 2015. Programme reports five month vaccine stock-out at national level. Estimate of 71 percent changed from previous revision value of 73 percent. GoC=R+ S+ D+
- 2015: Estimate based on coverage reported by national government supported by survey. Survey evidence of 71 percent based on 1 survey(s). Iraq Multiple Indicator Cluster Survey 2018 card or history results of 64 percent modified for recall bias to 71 percent based on 1st dose card or history coverage of 84 percent, 1st dose card only coverage of 59 percent and 3rd dose card only coverage of 50 percent. Programme reports a 5 month national level stock-out of DTP-HepB-Hib vaccine. Estimate challenged by: D-
- 2014: Reported data calibrated to 2010 and 2015 levels. Programme reports four months stock-out at national level. Reported number of children vaccinated is increasing since 2012 but continues to fall short of the reported number of children vaccinated with DTP containing vaccines during 2011. Estimate of 73 percent changed from previous revision value of 72 percent. Estimate challenged by: D-R-
- 2013: Reported data calibrated to 2010 and 2015 levels. Estimate of 73 percent changed from previous revision value of 74 percent. Estimate challenged by: D-R-
- 2012: Reported data calibrated to 2010 and 2015 levels. DTP-HepB-Hib pentavalent and DTP-Hib tetravalent vaccines introduced in 2012. Estimate of 72 percent changed from previous revision value of 73 percent. Estimate challenged by: D-R-
- 2011: Reported data calibrated to 2010 and 2015 levels. Estimate challenged by: D-R-
- 2010: Estimate of 74 percent assigned by working group. Estimate is based on survey results. Iraq Multiple Indicator Cluster Survey 2011 card or history results of 70 percent modified for recall bias to 74 percent based on 1st dose card or history coverage of 86 percent, 1st dose card only coverage of 66 percent and 3rd dose card only coverage of 57 percent. Estimate challenged by: D-R-
- 2009: Estimate of 78 percent assigned by working group. Estimate is based on survey results. Iraq Multiple Indicator Cluster Survey 2011 card or history results of 73 percent modified for recall bias to 78 percent based on 1st dose card or history coverage of 88 percent, 1st dose card only coverage of 63 percent and 3rd dose card only coverage of 56 percent. Estimate challenged by: D-R-

Iraq - Pol3

IRQ - Pol3



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | 78 | 74 | 82 | 73 | 75 | 76 | 72 | 76 | 82 | 74 | 85 | 78 |
| Estimate GoC | • | • | • | • | • | • | • | ••• | ••• | ••• | •• | •• |
| Official | 86 | 83 | 89 | 79 | 78 | 78 | 72 | 76 | 82 | 74 | 85 | 78 |
| Administrative | 86 | 83 | 89 | 79 | 78 | 78 | 72 | 76 | 82 | 74 | 85 | 77 |
| Survey | 79 | 76 | NA | NA | NA | NA | 71 | 74 | NA | NA | NA | NA |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2020: Estimate based on coverage reported by national government. GoC=R+ D+
- 2019: Estimate based on coverage reported by national government. Reported data suggests recovery following vaccine supply disruption. GoC=R+ D+
- 2018: Estimate based on coverage reported by national government. Programme reports three month vaccine stock-out at national level. Estimate of 74 percent changed from previous revision value of 71 percent. GoC=R+ S+ D+
- 2017: Estimate based on coverage reported by national government. Estimate of 82 percent changed from previous revision value of 86 percent. GoC=R+ S+ D+
- 2016: Estimate based on coverage reported by national government supported by survey. Survey evidence of 80 percent based on 1 survey(s). Iraq Multiple Indicator Cluster Survey 2018 card or history results of 74 percent modified for recall bias to 80 percent based on 1st dose card or history coverage of 91 percent, 1st dose card only coverage of 74 percent and 3rd dose card only coverage of 65 percent. Programme reports an unexplained decline in the target population of 15 percent from that reported in 2015. Programme reports one month vaccine stock-out at national level. Estimate of 76 percent changed from previous revision value of 77 percent. GoC=R+ S+ D+
- 2015: Estimate based on coverage reported by national government supported by survey. Survey evidence of 80 percent based on 1 survey(s). Iraq Multiple Indicator Cluster Survey 2018 card or history results of 71 percent modified for recall bias to 80 percent based on 1st dose card or history coverage of 90 percent, 1st dose card only coverage of 62 percent and 3rd dose card only coverage of 55 percent. Estimate challenged by: D-
- 2014: Reported data calibrated to 2010 and 2015 levels. Estimate of 76 percent changed from previous revision value of 74 percent. Estimate challenged by: D-R-
- 2013: Reported data calibrated to 2010 and 2015 levels. Estimate of 75 percent changed from previous revision value of 76 percent. Estimate challenged by: D-R-
- 2012: Reported data calibrated to 2010 and 2015 levels. Estimate challenged by: D-R-
- 2011: Reported data calibrated to 2010 and 2015 levels. Estimate challenged by: D-R-
- 2010: Estimate of 74 percent assigned by working group. Card-based evidence from the 2010 MICS results shows identical coverage levels for Pol3 and DTP3. Estimate follows estimated DTP3 coverage. Iraq Multiple Indicator Cluster Survey 2011 results ignored by working group. Recall-based survey results likely include campaign doses. Survey results ignored. Iraq Multiple Indicator Cluster Survey 2011 card or history results of 76 percent modified for recall bias to 77 percent based on 1st dose card or history coverage of 91 percent, 1st dose card only coverage of 67 percent and 3rd dose card only coverage of 57 percent. Estimate challenged by: D-R-
- 2009: Estimate of 78 percent assigned by working group. Card-based evidence from the 2010 MICS results shows identical coverage levels for Pol3 and DTP3. Estimate follows estimated DTP3 coverage. Iraq Multiple Indicator Cluster Survey 2011 card or history results of 79 percent modified for recall bias to 82 percent based on 1st dose card or history coverage of 92 percent, 1st dose card only coverage of 63 percent and 3rd dose card only coverage of 56 percent. Estimate challenged by: D-R-

Iraq - IPV1

IRQ - IPV1



Description:

Estimates for a dose of inactivated polio vaccine (IPV) begin in 2015 following the Global Polio Eradication Initiative's Polio Eradication and Endgame Strategic Plan: 2013-2018 which recommended at least one full dose or two fractional doses of IPV into routine immunization schedules as a strategy to mitigate the potential consequences should any re-emergence of type 2 poliovirus occur following the planned withdrawal of Sabin type 2 strains from oral polio vaccine (OPV).

2020: Estimate based on coverage reported by national government. Estimate based on reported data. GoC=R+ D+

2019: Estimate based on coverage reported by national government. GoC=R+ D+

2018: Estimate based on coverage reported by national government. Estimate of 94 percent changed from previous revision value of 92 percent. GoC=R+ D+

2017: Estimate based on coverage reported by national government. Estimate of 89 percent changed from previous revision value of 93 percent. GoC=R+ D+

| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | NA | NA | NA | NA | NA | NA | NA | NA | 89 | 94 | 93 | 77 |
| Estimate GoC | NA | NA | NA | NA | NA | NA | NA | NA | •• | •• | •• | •• |
| Official | NA | NA | NA | NA | NA | NA | NA | NA | 89 | 94 | 93 | 77 |
| Administrative | NA | NA | NA | NA | NA | NA | NA | NA | 89 | 94 | 93 | 77 |
| Survey | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |


The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Iraq - MCV1

IRQ - MCV1



Description:

- 2020: Estimate based on coverage reported by national government. GoC=R+ D+
- 2019: Estimate based on coverage reported by national government. GoC=R+ D+
- 2018: Estimate based on coverage reported by national government. Estimate of 85 percent changed from previous revision value of 83 percent. Estimate challenged by: S-
- 2017: Estimate based on coverage reported by national government. Estimate of 81 percent changed from previous revision value of 85 percent. GoC=R+ S+ D+
- 2016: Estimate based on coverage reported by national government supported by survey. Survey evidence of 71 percent based on 1 survey(s). Programme reports an unexplained decline in the target population of 15 percent from that reported in 2015. Programme reports three month vaccine stock-out at national level. Estimate of 79 percent changed from previous revision value of 80 percent. GoC=R+ S+ D+
- 2015: Estimate based on coverage reported by national government supported by survey. Survey evidence of 72 percent based on 1 survey(s). Estimate challenged by: D-
- 2014: Reported data calibrated to 2010 and 2015 levels. Programme reports five months stock-out of measles containing vaccine at national level. Estimate of 70 percent changed from previous revision value of 68 percent. Estimate challenged by: D-R-
- 2013: Reported data calibrated to 2010 and 2015 levels. Estimate of 73 percent changed from previous revision value of 72 percent. Estimate challenged by: D-R-
- 2012: Reported data calibrated to 2010 and 2015 levels. Estimate challenged by: D-R-
- 2011: Reported data calibrated to 2010 and 2015 levels. Estimate challenged by: D-R-
- 2010: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 75 percent based on 1 survey(s). Estimate challenged by: D-R-
- 2009: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 81 percent based on 1 survey(s). Estimate challenged by: D-R-

| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | 81 | 75 | 80 | 74 | 73 | 70 | 71 | 79 | 81 | 85 | 82 | 76 |
| Estimate GoC | • | • | • | • | • | • | • | ••• | ••• | • | •• | •• |
| Official | 97 | 89 | 91 | 83 | 78 | 73 | 71 | 79 | 81 | 85 | 82 | 76 |
| Administrative | 97 | 89 | 91 | 83 | 78 | 73 | 71 | 79 | 81 | 85 | 82 | 76 |
| Survey | 81 | 75 | NA | NA | NA | NA | 72 | 71 | NA | NA | NA | NA |


The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Iraq - MCV2

IRQ - MCV2



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | 87 | 77 | 77 | 68 | 57 | 67 | 76 | 75 | 84 | 83 | 86 | 93 |
| Estimate GoC | • | • | • | • | • | • | • | ••• | • | •• | •• | •• |
| Official | 102 | 91 | 90 | 81 | 71 | 78 | 76 | 75 | 84 | 83 | 86 | 93 |
| Administrative | 102 | 91 | 90 | 81 | 71 | 78 | 76 | 75 | 84 | 83 | 86 | 93 |
| Survey | NA | NA | NA | NA | NA | NA | 66 | NA | NA | NA | NA | NA |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

Coverage estimates for the second dose of measles containing vaccine are for children by the nationally recommended age.

2020: Estimate based on coverage reported by national government. Estimate based on reported data. Coverage may include MCV1 doses, country reports that information system does not allow recording delayed MCV1 doses. GoC=R+ D+

2019: Estimate based on coverage reported by national government. GoC=R+ D+

2018: Estimate based on coverage reported by national government. Estimate of 83 percent changed from previous revision value of 81 percent. GoC=R+ D+

2017: Estimate based on coverage reported by national government. Estimate of 84 percent changed from previous revision value of 88 percent. Estimate challenged by: S-

2016: Estimate based on coverage reported by national government. Programme reports an unexplained decline in the target population of 15 percent from that reported in 2015. Estimate of 75 percent changed from previous revision value of 78 percent. GoC=R+ S+ D+

2015: Estimate based on coverage reported by national government supported by survey. Survey evidence of 66 percent based on 1 survey(s). Estimate challenged by: D-

2014: Reported data calibrated to 2013 and 2015 levels. Reported data excluded. Programme reports five months stock-out of measles containing vaccine at national level. There is no apparent impact of the stock-out on reported coverage. In fact, counterintuitively the reported administrative coverage increased. Estimate challenged by: D-R-

2013: Estimate of 57 percent assigned by working group. Estimate follows reported data calibrated based on MCV adjustment factor. Estimate challenged by: D-R-

2012: Estimate of 68 percent assigned by working group. Estimate follows reported data calibrated based on MCV adjustment factor. Estimate challenged by: D-R-


2011: Estimate of 77 percent assigned by working group. Estimate follows reported data calibrated based on MCV adjustment factor. Estimate challenged by: D-R-

2010: Estimate of 77 percent assigned by working group. Estimate follows reported data calibrated based on MCV adjustment factor. Estimate challenged by: D-R-

2009: Estimate follows reported data calibrated based on MCV adjustment factor. Reported data excluded because 102 percent greater than 100 percent. Estimate challenged by: D-

Iraq - RCV1

IRQ - RCV1



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | 87 | 77 | 77 | 68 | 57 | 67 | 76 | 75 | 84 | 83 | 86 | 93 |
| Estimate GoC | • | • | • | • | • | • | • | ••• | • | •• | •• | •• |
| Official | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Administrative | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Survey | NA | NA | NA | NA | NA | NA | 66 | NA | NA | NA | NA | NA |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.


Description:

For this revision, coverage estimates for the first dose of rubella containing vaccine are based on WHO and UNICEF estimates of coverage of measles containing vaccine. Nationally reported coverage of rubella containing vaccine is not taken into consideration nor are they represented in the the accompanying graph and data table.

- 2020: First dose of rubella vaccine given with second dose of measles containing vaccine. Estimate based on MCV2 estimate GoC=R+ D+
- 2019: First dose of rubella vaccine given with second dose of measles containing vaccine. Estimate based on MCV2 estimate GoC=R+ D+
- 2018: First dose of rubella vaccine given with second dose of measles containing vaccine. Estimate based on MCV2 estimate Estimate of 83 percent changed from previous revision value of 81 percent. GoC=R+ D+
- 2017: First dose of rubella vaccine given with second dose of measles containing vaccine. Estimate based on MCV2 estimate Estimate of 84 percent changed from previous revision value of 88 percent. Estimate challenged by: S-
- 2016: First dose of rubella vaccine given with second dose of measles containing vaccine. Estimate based on MCV2 estimate Programme reports an unexplained decline in the target population of 15 percent from that reported in 2015. Estimate of 75 percent changed from previous revision value of 78 percent. GoC=R+ S+ D+
- 2015: First dose of rubella vaccine given with second dose of measles containing vaccine. Estimate based on MCV2 estimate Estimate challenged by: D-
- 2014: First dose of rubella vaccine given with second dose of measles containing vaccine. Estimate based on MCV2 estimate Estimate challenged by: D-R-
- 2013: First dose of rubella vaccine given with second dose of measles containing vaccine. Estimate based on MCV2 estimate Estimate challenged by: D-R-
- 2012: First dose of rubella vaccine given with second dose of measles containing vaccine. Estimate based on MCV2 estimate Estimate challenged by: D-R-
- 2011: First dose of rubella vaccine given with second dose of measles containing vaccine. Estimate based on MCV2 estimate Estimate challenged by: D-R-
- 2010: First dose of rubella vaccine given with second dose of measles containing vaccine. Estimate based on MCV2 estimate Estimate challenged by: D-R-
- 2009: First dose of rubella vaccine given with second dose of measles containing vaccine. Estimate based on MCV2 estimate Estimate challenged by: D-

Iraq - HepBB

IRQ - HepBB



Description:

- 2020: Estimate based on coverage reported by national government. GoC=R+ D+
- 2019: Estimate based on coverage reported by national government. Estimate of 51 percent changed from previous revision value of 41 percent. GoC=R+
- 2018: Estimate based on coverage reported by national government. Programme reports one month vaccine stock-out at national level. Estimate of 42 percent changed from previous revision value of 41 percent. GoC=R+ D+
- 2017: Estimate based on coverage reported by national government. GoC=R+ D+
- 2016: Estimate based on coverage reported by national government. Iraq Multiple Indicator Cluster Survey 2018 results ignored by working group. Survey may not differentiate from doses given within 24hrs to other doses. Programme reports an unexplained decline in the target population of 15 percent from that reported in 2015. Estimate of 45 percent changed from previous revision value of 47 percent. GoC=R+ D+
- 2015: Estimate based on coverage reported by national government. Iraq Multiple Indicator Cluster Survey 2018 results ignored by working group. Survey may not differentiate from doses given within 24hrs to other doses. GoC=R+ D+
- 2014: Estimate based on coverage reported by national government. Estimate of 44 percent changed from previous revision value of 43 percent. GoC=R+ D+
- 2013: Estimate based on coverage reported by national government. Estimate challenged by: D-
- 2012: Estimate based on coverage reported by national government. GoC=R+ D+
- 2011: Estimate based on interpolation between reported values. GoC=No accepted empirical data
- 2010: Estimate based on coverage reported by national government. Decline in coverage is unexplained. GoC=R+ D+
- 2009: Estimate based on interpolation between reported values. GoC=No accepted empirical data

| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | 60 | 27 | 32 | 37 | 43 | 44 | 43 | 45 | 44 | 42 | 51 | 47 |
| Estimate GoC | • | •• | • | •• | • | •• | •• | •• | •• | •• | •• | •• |
| Official | NA | 27 | NA | 37 | 43 | 44 | 43 | 45 | 44 | 42 | 51 | 47 |
| Administrative | NA | 27 | NA | 37 | 43 | 44 | 43 | 45 | 44 | 42 | 51 | 47 |
| Survey | NA | NA | NA | NA | NA | NA | 63 | 74 | NA | NA | NA | NA |


The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Iraq - HepB3

IRQ - HepB3



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | 75 | 72 | 78 | 65 | 68 | 69 | 68 | 71 | 81 | 86 | 84 | 74 |
| Estimate GoC | • | • | • | • | • | • | • | ••• | ••• | • | •• | •• |
| Official | 86 | 84 | 89 | 77 | 79 | 75 | 68 | 71 | 81 | 86 | 84 | 74 |
| Administrative | 86 | 84 | 89 | 77 | 79 | 75 | 68 | 71 | 81 | 86 | 84 | 74 |
| Survey | 68 | 66 | NA | NA | NA | NA | 64 | 69 | NA | NA | NA | NA |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2020: Estimate based on coverage reported by national government. GoC=R+
- 2019: Estimate based on coverage reported by national government. GoC=R+ D+
- 2018: Estimate based on coverage reported by national government. Estimate of 86 percent changed from previous revision value of 84 percent. Estimate challenged by: S-
- 2017: Estimate based on coverage reported by national government. Estimate of 81 percent changed from previous revision value of 85 percent. GoC=R+ S+ D+
- 2016: Estimate based on coverage reported by national government supported by survey. Survey evidence of 73 percent based on 1 survey(s). Iraq Multiple Indicator Cluster Survey 2018 card or history results of 69 percent modified for recall bias to 73 percent based on 1st dose card or history coverage of 86 percent, 1st dose card only coverage of 73 percent and 3rd dose card only coverage of 62 percent. Programme reports an unexplained decline in the target population of 15 percent from that reported in 2015. Programme reports five month vaccine stock-out at national level. Estimate of 71 percent changed from previous revision value of 73 percent. GoC=R+ S+ D+
- 2015: Estimate based on coverage reported by national government supported by survey. Survey evidence of 71 percent based on 1 survey(s). Iraq Multiple Indicator Cluster Survey 2018 card or history results of 64 percent modified for recall bias to 71 percent based on 1st dose card or history coverage of 84 percent, 1st dose card only coverage of 59 percent and 3rd dose card only coverage of 50 percent. Programme reports a 5 month national level stock-out of DTP-HepB-Hib vaccine. Estimate challenged by: D-
- 2014: Reported data calibrated to 2013 and 2015 levels. Programme reports four months stock-out at national level. Estimate challenged by: D-R-
- 2013: Estimate of 68 percent assigned by working group. Estimate based on DTP3 estimate. Estimate challenged by: D-R-
- 2012: Reported data calibrated to 2010 and 2013 levels. DTP-HepB-Hib pentavalent vaccine introduced in 2012. Estimate of 65 percent changed from previous revision value of 62 percent. Estimate challenged by: D-R-
- 2011: Reported data calibrated to 2010 and 2013 levels. Estimate challenged by: D-R-
- 2010: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 72 percent based on 1 survey(s). Iraq Multiple Indicator Cluster Survey 2011 card or history results of 66 percent modified for recall bias to 72 percent based on 1st dose card or history coverage of 89 percent, 1st dose card only coverage of 70 percent and 3rd dose card only coverage of 57 percent. Estimate challenged by: D-R-
- 2009: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 75 percent based on 1 survey(s). Iraq Multiple Indicator Cluster Survey 2011 card or history results of 68 percent modified for recall bias to 75 percent based on 1st dose card or history coverage of 90 percent, 1st dose card only coverage of 66 percent and 3rd dose card only coverage of 55 percent. Estimate challenged by: D-R-

Iraq - Hib3

IRQ - Hib3



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | NA | NA | NA | 36 | 68 | 70 | 68 | 71 | 81 | 86 | 84 | 74 |
| Estimate GoC | NA | NA | NA | • | • | • | • | ••• | ••• | • | •• | •• |
| Official | NA | NA | NA | 46 | 78 | 75 | 68 | 71 | 81 | 86 | 84 | 74 |
| Administrative | NA | NA | NA | 46 | 78 | 75 | 68 | 71 | 81 | 86 | 84 | 74 |
| Survey | NA | NA | NA | NA | NA | NA | 64 | 69 | NA | NA | NA | NA |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2020: Estimate based on coverage reported by national government. GoC=R+
- 2019: Estimate based on coverage reported by national government. GoC=R+ D+
- 2018: Estimate based on coverage reported by national government. Estimate of 86 percent changed from previous revision value of 84 percent. Estimate challenged by: S-
- 2017: Estimate based on coverage reported by national government. Estimate of 81 percent changed from previous revision value of 85 percent. GoC=R+ S+ D+
- 2016: Estimate based on coverage reported by national government supported by survey. Survey evidence of 73 percent based on 1 survey(s). Iraq Multiple Indicator Cluster Survey 2018 card or history results of 69 percent modified for recall bias to 73 percent based on 1st dose card or history coverage of 86 percent, 1st dose card only coverage of 73 percent and 3rd dose card only coverage of 62 percent. Programme reports an unexplained decline in the target population of 15 percent from that reported in 2015. Programme reports five month vaccine stock-out at national level. Estimate of 71 percent changed from previous revision value of 73 percent. GoC=R+ S+ D+
- 2015: Estimate based on coverage reported by national government supported by survey. Survey evidence of 71 percent based on 1 survey(s). Iraq Multiple Indicator Cluster Survey 2018 card or history results of 64 percent modified for recall bias to 71 percent based on 1st dose card or history coverage of 84 percent, 1st dose card only coverage of 59 percent and 3rd dose card only coverage of 50 percent. Programme reports a 5 month national level stock-out of DTP-HepB-Hib vaccine. Estimate challenged by: D-
- 2014: Reported data calibrated to 2013 and 2015 levels. Programme reports four months stock-out at national level. Estimate of 70 percent changed from previous revision value of 69 percent. Estimate challenged by: D-R-
- 2013: Estimate of 68 percent assigned by working group. Estimate is based on DTP3 coverage level. Estimate challenged by: D-R-
- 2012: Reported data calibrated to 2013 levels. Hib vaccine introduced in 2012. The presentations are DTP-Hib and DTP-HepB-Hib. Estimate challenged by: D-R-

Iraq - RotaC

IRQ - RotaC



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | NA | NA | NA | 31 | 52 | 30 | 43 | 52 | 63 | 60 | 5 | 42 |
| Estimate GoC | NA | NA | NA | ●● | ● | ●● | ●● | ●● | ●● | ●● | ●● | ●● |
| Official | NA | NA | NA | 31 | 52 | 30 | 34 | 52 | 63 | 60 | 5 | 42 |
| Administrative | NA | NA | NA | 31 | 52 | 30 | 43 | 52 | 63 | 61 | 5 | 42 |
| Survey | NA | NA | NA | NA | NA | NA | 58 | 61 | NA | NA | NA | NA |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2020: Estimate based on coverage reported by national government. GoC=R+ D+
- 2019: Estimate based on coverage reported by national government. Programme reports a 10 month vaccine stock-out at national and district levels. GoC=R+ D+
- 2018: Estimate based on coverage reported by national government. Programme reports seven month vaccine stock-out at national level. GoC=R+ D+
- 2017: Estimate based on coverage reported by national government. GoC=R+ D+
- 2016: Estimate based on coverage reported by national government. Iraq Multiple Indicator Cluster Survey 2018 results ignored by working group. Survey results inconsistent with reported data and contextual information suggesting the occurrence of vaccine stock-out during the survey period. Programme reports an unexplained decline in the target population of 15 percent from that reported in 2015. Programme reports two month vaccine stock-out at national level. Estimate of 52 percent changed from previous revision value of 53 percent. GoC=R+
- 2015: Estimate based on reported administrative estimate. Iraq Multiple Indicator Cluster Survey 2018 results ignored by working group. Survey results inconsistent with reported data and contextual information suggesting the occurrence of vaccine stock-out during the survey period. . GoC=R+ D+
- 2014: Estimate based on reported administrative estimate. Estimate is based on reported data. Programme reports five months stock-out at national level. Estimate of 30 percent changed from previous revision value of 29 percent. GoC=R+ D+
- 2013: Estimate based on coverage reported by national government. Estimate is based on reported data. Estimate challenged by: D-
- 2012: Estimate based on coverage reported by national government. Rotavirus vaccine introduced in 2012. GoC=R+ D+

Iraq - PcV3

IRQ - PcV3



Description:

- 2020: Estimate based on coverage reported by national government. Programme reports a 12-month vaccine stock-out. GoC=R+
- 2019: Estimate based on coverage reported by national government. Programme reports a 12-month vaccine stock-out at national and district levels. GoC=R+ D+
- 2018: Estimate based on coverage reported by national government. Programme reports six-month vaccine stock-out at national level. Estimate of 33 percent changed from previous revision value of 32 percent. GoC=R+ D+
- 2017: Estimate based on coverage reported by national government. Pneumococcal conjugate vaccine introduced March 2017. GoC=R+ D+

| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate | NA | NA | NA | NA | NA | NA | NA | NA | 33 | 33 | 37 | 0 |
| Estimate GoC | NA | NA | NA | NA | NA | NA | NA | NA | •• | •• | •• | •• |
| Official | NA | NA | NA | NA | NA | NA | NA | NA | 33 | 33 | 37 | 0 |
| Administrative | NA | NA | NA | NA | NA | NA | NA | NA | 33 | 33 | 37 | 0 |
| Survey | NA | NA | NA | NA | NA | NA | 15 | 29 | NA | NA | NA | NA |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2020 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Iraq - survey details

2016 Iraq Multiple Indicator Cluster Survey 2018

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG | C or H <12 months | 94.3 | 12-23 m | 3167 | 79 |
| BCG | Card | 77.4 | 12-23 m | 3167 | 79 |
| BCG | Card or History | 94.7 | 12-23 m | 3167 | 79 |
| BCG | History | 17.2 | 12-23 m | 3167 | 79 |
| DTP1 | C or H <12 months | 84.6 | 12-23 m | 3167 | 79 |
| DTP1 | Card | 73.3 | 12-23 m | 3167 | 79 |
| DTP1 | Card or History | 85.9 | 12-23 m | 3167 | 79 |
| DTP1 | History | 12.6 | 12-23 m | 3167 | 79 |
| DTP3 | C or H <12 months | 64.3 | 12-23 m | 3167 | 79 |
| DTP3 | Card | 62.5 | 12-23 m | 3167 | 79 |
| DTP3 | Card or History | 68.8 | 12-23 m | 3167 | 79 |
| DTP3 | History | 6.3 | 12-23 m | 3167 | 79 |
| HepB1 | C or H <12 months | 84.6 | 12-23 m | 3167 | 79 |
| HepB1 | Card | 73.3 | 12-23 m | 3167 | 79 |
| HepB1 | Card or History | 85.9 | 12-23 m | 3167 | 79 |
| HepB1 | History | 12.6 | 12-23 m | 3167 | 79 |
| HepB3 | C or H <12 months | 64.3 | 12-23 m | 3167 | 79 |
| HepB3 | Card | 62.5 | 12-23 m | 3167 | 79 |
| HepB3 | Card or History | 68.8 | 12-23 m | 3167 | 79 |
| HepB3 | History | 6.3 | 12-23 m | 3167 | 79 |
| HepBB | C or H <12 months | 74.4 | 12-23 m | 3167 | 79 |
| HepBB | Card | 72.5 | 12-23 m | 3167 | 79 |
| HepBB | Card or History | 74.4 | 12-23 m | 3167 | 79 |
| HepBB | History | 1.9 | 12-23 m | 3167 | 79 |
| Hib1 | C or H <12 months | 84.6 | 12-23 m | 3167 | 79 |
| Hib1 | Card | 73.3 | 12-23 m | 3167 | 79 |
| Hib1 | Card or History | 85.9 | 12-23 m | 3167 | 79 |
| Hib1 | History | 12.6 | 12-23 m | 3167 | 79 |
| Hib3 | C or H <12 months | 64.3 | 12-23 m | 3167 | 79 |
| Hib3 | Card | 62.5 | 12-23 m | 3167 | 79 |
| Hib3 | Card or History | 68.8 | 12-23 m | 3167 | 79 |
| Hib3 | History | 6.3 | 12-23 m | 3167 | 79 |
| MCV1 | C or H <12 months | 65.6 | 12-23 m | 3167 | 79 |
| MCV1 | Card | 60.4 | 12-23 m | 3167 | 79 |
| MCV1 | Card or History | 71 | 12-23 m | 3167 | 79 |
| MCV1 | History | 10.6 | 12-23 m | 3167 | 79 |
| PcV1 | C or H <12 months | 37.3 | 12-23 m | 3167 | 79 |

| | | | | | |
|-------|-------------------|------|---------|------|----|
| PcV1 | Card | 32.1 | 12-23 m | 3167 | 79 |
| PcV1 | Card or History | 38.1 | 12-23 m | 3167 | 79 |
| PcV1 | History | 6 | 12-23 m | 3167 | 79 |
| PcV3 | C or H <12 months | 27 | 12-23 m | 3167 | 79 |
| PcV3 | Card | 25.8 | 12-23 m | 3167 | 79 |
| PcV3 | Card or History | 28.6 | 12-23 m | 3167 | 79 |
| PcV3 | History | 2.9 | 12-23 m | 3167 | 79 |
| Pol1 | C or H <12 months | 89.5 | 12-23 m | 3167 | 79 |
| Pol1 | Card | 74.5 | 12-23 m | 3167 | 79 |
| Pol1 | Card or History | 90.9 | 12-23 m | 3167 | 79 |
| Pol1 | History | 16.4 | 12-23 m | 3167 | 79 |
| Pol3 | C or H <12 months | 69.1 | 12-23 m | 3167 | 79 |
| Pol3 | Card | 64.9 | 12-23 m | 3167 | 79 |
| Pol3 | Card or History | 73.6 | 12-23 m | 3167 | 79 |
| Pol3 | History | 8.7 | 12-23 m | 3167 | 79 |
| RotaC | C or H <12 months | 59.8 | 12-23 m | 3167 | 79 |
| RotaC | Card | 54 | 12-23 m | 3167 | 79 |
| RotaC | Card or History | 60.6 | 12-23 m | 3167 | 79 |
| RotaC | History | 6.6 | 12-23 m | 3167 | 79 |

2015 Iraq Multiple Indicator Cluster Survey 2018

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG | C or H <12 months | 93.3 | 24-35 m | 3089 | 79 |
| BCG | Card | 65.1 | 24-35 m | 3089 | 79 |
| BCG | Card or History | 93.9 | 24-35 m | 3089 | 79 |
| BCG | History | 28.8 | 24-35 m | 3089 | 79 |
| DTP1 | C or H <12 months | 81.3 | 24-35 m | 3089 | 79 |
| DTP1 | Card | 59.1 | 24-35 m | 3089 | 79 |
| DTP1 | Card or History | 83.6 | 24-35 m | 3089 | 79 |
| DTP1 | History | 24.5 | 24-35 m | 3089 | 79 |
| DTP3 | C or H <12 months | 57.7 | 24-35 m | 3089 | 79 |
| DTP3 | Card | 50.2 | 24-35 m | 3089 | 79 |
| DTP3 | Card or History | 63.5 | 24-35 m | 3089 | 79 |
| DTP3 | History | 13.3 | 24-35 m | 3089 | 79 |
| HepB1 | C or H <12 months | 81.3 | 24-35 m | 3089 | 79 |
| HepB1 | Card | 59.1 | 24-35 m | 3089 | 79 |
| HepB1 | Card or History | 83.6 | 24-35 m | 3089 | 79 |
| HepB1 | History | 24.5 | 24-35 m | 3089 | 79 |

Iraq - survey details

| | | | | | |
|-------|-------------------|------|---------|------|----|
| HepB3 | C or H <12 months | 57.7 | 24-35 m | 3089 | 79 |
| HepB3 | Card | 50.2 | 24-35 m | 3089 | 79 |
| HepB3 | Card or History | 63.5 | 24-35 m | 3089 | 79 |
| HepB3 | History | 13.3 | 24-35 m | 3089 | 79 |
| HepBB | C or H <12 months | 62.5 | 24-35 m | 3089 | 79 |
| HepBB | Card | 61.7 | 24-35 m | 3089 | 79 |
| HepBB | Card or History | 62.9 | 24-35 m | 3089 | 79 |
| HepBB | History | 1.1 | 24-35 m | 3089 | 79 |
| Hib1 | C or H <12 months | 81.3 | 24-35 m | 3089 | 79 |
| Hib1 | Card | 59.1 | 24-35 m | 3089 | 79 |
| Hib1 | Card or History | 83.6 | 24-35 m | 3089 | 79 |
| Hib1 | History | 24.5 | 24-35 m | 3089 | 79 |
| Hib3 | C or H <12 months | 57.7 | 24-35 m | 3089 | 79 |
| Hib3 | Card | 50.2 | 24-35 m | 3089 | 79 |
| Hib3 | Card or History | 63.5 | 24-35 m | 3089 | 79 |
| Hib3 | History | 13.3 | 24-35 m | 3089 | 79 |
| MCV1 | C or H <12 months | 63.3 | 24-35 m | 3089 | 79 |
| MCV1 | Card | 51 | 24-35 m | 3089 | 79 |
| MCV1 | Card or History | 71.9 | 24-35 m | 3089 | 79 |
| MCV1 | History | 20.9 | 24-35 m | 3089 | 79 |
| MCV2 | C or H <24 months | 63.1 | 24-35 m | 3089 | 79 |
| MCV2 | Card | 48 | 24-35 m | 3089 | 79 |
| MCV2 | Card or History | 66.4 | 24-35 m | 3089 | 79 |
| MCV2 | History | 18.5 | 24-35 m | 3089 | 79 |
| PcV1 | C or H <12 months | 22.6 | 24-35 m | 3089 | 79 |
| PcV1 | Card | 13.9 | 24-35 m | 3089 | 79 |
| PcV1 | Card or History | 23.9 | 24-35 m | 3089 | 79 |
| PcV1 | History | 10 | 24-35 m | 3089 | 79 |
| PcV3 | C or H <12 months | 13.6 | 24-35 m | 3089 | 79 |
| PcV3 | Card | 11.6 | 24-35 m | 3089 | 79 |
| PcV3 | Card or History | 15.4 | 24-35 m | 3089 | 79 |
| PcV3 | History | 3.8 | 24-35 m | 3089 | 79 |
| Pol1 | C or H <12 months | 87.2 | 24-35 m | 3089 | 79 |
| Pol1 | Card | 61.7 | 24-35 m | 3089 | 79 |
| Pol1 | Card or History | 89.5 | 24-35 m | 3089 | 79 |
| Pol1 | History | 27.8 | 24-35 m | 3089 | 79 |
| Pol3 | C or H <12 months | 65 | 24-35 m | 3089 | 79 |
| Pol3 | Card | 54.7 | 24-35 m | 3089 | 79 |
| Pol3 | Card or History | 70.9 | 24-35 m | 3089 | 79 |
| Pol3 | History | 16.2 | 24-35 m | 3089 | 79 |

| | | | | | |
|-------|-------------------|------|---------|------|----|
| RotaC | C or H <12 months | 56.5 | 24-35 m | 3089 | 79 |
| RotaC | Card | 45.3 | 24-35 m | 3089 | 79 |
| RotaC | Card or History | 58.4 | 24-35 m | 3089 | 79 |
| RotaC | History | 13 | 24-35 m | 3089 | 79 |

2010 Iraq Multiple Indicator Cluster Survey 2011

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG | C or H <12 months | 89.7 | 12-23 m | - | 70 |
| BCG | Card | 68.3 | 12-23 m | - | 70 |
| BCG | Card or History | 90.4 | 12-23 m | 7487 | 70 |
| BCG | History | 22.1 | 12-23 m | - | 70 |
| DTP1 | C or H <12 months | 84.9 | 12-23 m | - | 70 |
| DTP1 | Card | 66.5 | 12-23 m | - | 70 |
| DTP1 | Card or History | 86.1 | 12-23 m | 7487 | 70 |
| DTP1 | History | 19.6 | 12-23 m | - | 70 |
| DTP3 | C or H <12 months | 64.8 | 12-23 m | - | 70 |
| DTP3 | Card | 57 | 12-23 m | - | 70 |
| DTP3 | Card or History | 70.1 | 12-23 m | 7487 | 70 |
| DTP3 | History | 13.1 | 12-23 m | - | 70 |
| HepB1 | C or H <12 months | 88.2 | 12-23 m | - | 70 |
| HepB1 | Card | 69.7 | 12-23 m | - | 70 |
| HepB1 | Card or History | 88.9 | 12-23 m | 7487 | 70 |
| HepB1 | History | 19.1 | 12-23 m | - | 70 |
| HepB3 | C or H <12 months | 61 | 12-23 m | - | 70 |
| HepB3 | Card | 56.9 | 12-23 m | - | 70 |
| HepB3 | Card or History | 66.1 | 12-23 m | 7487 | 70 |
| HepB3 | History | 9.2 | 12-23 m | - | 70 |
| MCV1 | C or H <12 months | 65.8 | 12-23 m | - | 70 |
| MCV1 | Card | 54 | 12-23 m | - | 70 |
| MCV1 | Card or History | 75.4 | 12-23 m | 7487 | 70 |
| MCV1 | History | 21.3 | 12-23 m | - | 70 |
| Pol1 | C or H <12 months | 89.6 | 12-23 m | - | 70 |
| Pol1 | Card | 66.6 | 12-23 m | - | 70 |
| Pol1 | Card or History | 90.8 | 12-23 m | 7487 | 70 |
| Pol1 | History | 24.2 | 12-23 m | - | 70 |
| Pol3 | C or H <12 months | 70.6 | 12-23 m | - | 70 |
| Pol3 | Card | 57.2 | 12-23 m | - | 70 |
| Pol3 | Card or History | 76.4 | 12-23 m | 7487 | 70 |

Iraq - survey details

Pol3 History 19.2 12-23 m - 70

2004 Iraq Multiple Indicator Cluster Survey 2006

2009 Iraq Multiple Indicator Cluster Survey 2011

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG | C or H <12 months | 91.2 | 18-29 m | - | 70 |
| BCG | Card | 65 | 18-29 m | - | 70 |
| BCG | Card or History | 92.4 | 18-29 m | 7524 | 70 |
| BCG | History | 27.4 | 18-29 m | - | 70 |
| DTP1 | C or H <12 months | 85.8 | 18-29 m | - | 70 |
| DTP1 | Card | 63.3 | 18-29 m | - | 70 |
| DTP1 | Card or History | 88 | 18-29 m | 7524 | 70 |
| DTP1 | History | 24.7 | 18-29 m | - | 70 |
| DTP3 | C or H <12 months | 65.1 | 18-29 m | - | 70 |
| DTP3 | Card | 55.5 | 18-29 m | - | 70 |
| DTP3 | Card or History | 73.2 | 18-29 m | 7524 | 70 |
| DTP3 | History | 17.8 | 18-29 m | - | 70 |
| HepB1 | C or H <12 months | 89.1 | 18-29 m | - | 70 |
| HepB1 | Card | 65.9 | 18-29 m | - | 70 |
| HepB1 | Card or History | 90.1 | 18-29 m | 7524 | 70 |
| HepB1 | History | 24.3 | 18-29 m | - | 70 |
| HepB3 | C or H <12 months | 60.2 | 18-29 m | - | 70 |
| HepB3 | Card | 55.1 | 18-29 m | - | 70 |
| HepB3 | Card or History | 67.7 | 18-29 m | 7524 | 70 |
| HepB3 | History | 12.6 | 18-29 m | - | 70 |
| MCV1 | C or H <18 months | 76.7 | 18-29 m | - | 70 |
| MCV1 | Card | 55.3 | 18-29 m | - | 70 |
| MCV1 | Card or History | 81.3 | 18-29 m | 7524 | 70 |
| MCV1 | History | 26 | 18-29 m | - | 70 |
| Pol1 | C or H <12 months | 90.2 | 18-29 m | - | 70 |
| Pol1 | Card | 63.2 | 18-29 m | - | 70 |
| Pol1 | Card or History | 92.4 | 18-29 m | 7524 | 70 |
| Pol1 | History | 29.2 | 18-29 m | - | 70 |
| Pol3 | C or H <12 months | 70.4 | 18-29 m | - | 70 |
| Pol3 | Card | 55.7 | 18-29 m | - | 70 |
| Pol3 | Card or History | 79.1 | 18-29 m | 7524 | 70 |
| Pol3 | History | 23.4 | 18-29 m | - | 70 |

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG | C or H <12 months | 91.4 | 18-29 m | 3329 | 55 |
| BCG | Card | 53.5 | 18-29 m | 3329 | 55 |
| BCG | Card or History | 92.3 | 18-29 m | 3329 | 55 |
| BCG | History | 38.8 | 18-29 m | 3329 | 55 |
| DTP1 | C or H <12 months | 81.9 | 18-29 m | 3329 | 55 |
| DTP1 | Card | 49 | 18-29 m | 3329 | 55 |
| DTP1 | Card or History | 84.5 | 18-29 m | 3329 | 55 |
| DTP1 | History | 35.5 | 18-29 m | 3329 | 55 |
| DTP3 | C or H <12 months | 52.8 | 18-29 m | 3329 | 55 |
| DTP3 | Card | 37.9 | 18-29 m | 3329 | 55 |
| DTP3 | Card or History | 61.5 | 18-29 m | 3329 | 55 |
| DTP3 | History | 23.6 | 18-29 m | 3329 | 55 |
| HepB1 | C or H <12 months | 87.1 | 18-29 m | 3329 | 55 |
| HepB1 | Card | 53.8 | 18-29 m | 3329 | 55 |
| HepB1 | Card or History | 88.3 | 18-29 m | 3329 | 55 |
| HepB1 | History | 34.5 | 18-29 m | 3329 | 55 |
| HepB3 | C or H <12 months | 49.4 | 18-29 m | 3329 | 55 |
| HepB3 | Card | 38.2 | 18-29 m | 3329 | 55 |
| HepB3 | Card or History | 57.6 | 18-29 m | 3329 | 55 |
| HepB3 | History | 19.4 | 18-29 m | 3329 | 55 |
| MCV1 | Card | 38.7 | 18-29 m | 3329 | 55 |
| MCV1 | Card or History | 69.3 | 18-29 m | 3329 | 55 |
| MCV1 | History | 30.6 | 18-29 m | 3329 | 55 |
| Pol1 | C or H <12 months | 87.7 | 18-29 m | 3329 | 55 |
| Pol1 | Card | 49.2 | 18-29 m | 3329 | 55 |
| Pol1 | Card or History | 90.8 | 18-29 m | 3329 | 55 |
| Pol1 | History | 41.6 | 18-29 m | 3329 | 55 |
| Pol3 | C or H <12 months | 57 | 18-29 m | 3329 | 55 |
| Pol3 | Card | 37.4 | 18-29 m | 3329 | 55 |
| Pol3 | Card or History | 65.6 | 18-29 m | 3329 | 55 |
| Pol3 | History | 28.2 | 18-29 m | 3329 | 55 |

1999 Iraq Multiple Indicator Cluster Survey 2000

Vaccine Confirmation method Coverage Age cohort Sample Cards seen

Iraq - survey details

| | | | | | | | | | | | |
|------|-----------------|------|---------|-----|----|------|-----------------|------|---------|-----|----|
| BCG | Card or History | 92.7 | 12-23 m | 434 | 78 | Pol1 | Card or History | 96 | 12-23 m | 434 | 78 |
| DTP1 | Card or History | 93 | 12-23 m | 434 | 78 | Pol3 | Card or History | 87.2 | 12-23 m | 434 | 78 |
| DTP3 | Card or History | 81.1 | 12-23 m | 434 | 78 | | | | | | |
| MCV1 | Card or History | 90 | 12-23 m | 434 | 78 | | | | | | |

Further information and estimates for previous years are available at:

<http://www.data.unicef.org/child-health/immunization>

<https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-insights/global-monitoring/data-statistics-and-graphics>